Results 61 to 70 of about 37,077 (282)

Antibody-Based Strategies to Prevent and Treat Influenza [PDF]

open access: yes, 2015
Passive immunization using antibodies is a promising alternative to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents.
Sasisekharan, Ram   +2 more
core   +1 more source

Bispecific Antibody-Functionalized Upconversion Nanoprobe [PDF]

open access: yesAnalytical Chemistry, 2018
Upconversion nanoparticles (UCNPs) are new optical probes for biological applications. For specific biomolecular recognition to be realized for diagnosis and imaging, the key lies in developing a stable and easy-to-use bioconjugation method for antibody modification.
Hao He   +7 more
openaire   +3 more sources

Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy

open access: yesAdvanced Science, EarlyView.
This review summarizes the emerging strategies for the precise regulation of membrane proteins using physical stimuli and biomolecule‐based tools. These methods provide new insights into cell regulation and offer promising directions for future disease treatment.
Xiu Zhao   +6 more
wiley   +1 more source

Engineering a novel IgG-like bispecific antibody against enterovirus A71

open access: yesBiochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang   +7 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen   +3 more
openaire   +2 more sources

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang   +10 more
wiley   +1 more source

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies

open access: yesFrontiers in Pharmacology
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu   +9 more
doaj   +1 more source

Immunity against fungal beta 1,3 glucan carbohydrate in the gastrointestinal tract [PDF]

open access: yes, 2016
Inflammatory Bowel Disease (IBD) is a debilitating, life- long disease that affects about 1.4 millions Americans. Little is known about the pathogenesis of IBD and an effective cure still remains to be discovered.
Feliu, Marianela
core   +1 more source

C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation [PDF]

open access: yes, 2015
Complement C1q is the activator of the classical pathway. However, it is now recognized that C1q can exert functions unrelated to complement activation.
Agostinis, C   +9 more
core   +3 more sources

cDC1 Subtype‐Specific In Vivo Targeting of Liposomes

open access: yesAdvanced Science, EarlyView.
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy